![ESMO-Deep-Dive-Upper-Digestive-Cancers-1000x250-Gastric-Cancer](/var/esmo/storage/images/media/esmo/meetings/2022/_webinars/webinar-series/deep-dive/esmo-deep-dive-upper-digestive-cancers-1000x250-gastric-cancer/9851674-3-eng-GB/esmo-deep-dive-upper-digestive-cancers-1000x250-gastric-cancer_i770.jpg)
ESMO Members: Take the CME test
and receive 2 ESMO - MORA point
Learning objectives:
- Understand how new genomic technologies such as single-cell analysis can improve our understanding of gastric cancer intra-tumour heterogeneity, which is emerging as a major barrier to clinical management
- Understand best practice in the treatment of MSI-H gastric cancer Immunobiology of the disease
- Understand how features of chromosomal instability lead to different patterns of oncogene activation in gastroesophageal cancers than other GI cancers such as colorectal and pancreatic
- Understand how intra-tumour heterogeneity can impact response to therapy and resistance
- Evaluate the need for refined biomarker testing approaches to confront the problems of heterogeneity and the features of chromosomal instability in GE cancers